iC1e/K for COVID-19: real-time analysis

Download Image

Post

c19early.org

iC1e/K for COVID-19

1 study with 20 patients

Serious outcome risk

iC1e/K

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 iC1e/K studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)0%

Mortality (1)0%

RCTs (1)0%

Late (1)0%

00.511.5+

← iC1e/K
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Feb 16 2021	Mansour et al., Viruses, doi:10.3390/v13020309	Safety and Outcomes Associated with the Pharmacological Inhibition of the Kinin–Kallikrein System in Severe COVID-19
Feb 16 2021	no change in mortality (p=1) and 35% lower hospital discharge (p=0.36). RCT 30 severe COVID-19 patients showing no significant difference in mortality or hospitalization time with kinin-kallikrein system inhibitors icatibant or iC1e/K. While there was no impact on mortality or hospitalization time, both treat..